BUSINESS● LOW9h ago · Oct 14, 2026, 4:53 PM
IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma
Seeking Alpha Tech · global
IDEAYA stock has resumed with a 'Buy' rating from Stifel, specifically noting its combination treatment for uveal melanoma. This indicates a positive market outlook for the company, tied to its medical advancements.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS54m agoSK Hynix shares plunge 10% amid Asia tech rout as Fed rate hike fears, AI funding worries mountCNBCBUSINESS1h agoIt's official | The IRS confirms that people with these jobs will deduct up to $25,000 from their annual federal taxes with Form W-2 if they meet these requirements.Clarín